celecoxib has been researched along with Body Weight in 38 studies
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| " We report in this study that a clinically available COX-2 inhibitor, celecoxib, exacerbates porcine serum (PS)-induced hepatic fibrosis and induces hepatocellular necrosis in an experimental liver fibrosis model." | 7.75 | Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. ( Li, X; Liu, H; Wei, W, 2009) |
| " The present study was designed to investigate the anti-proteinuric effects of nordihydroguaiaretic acid (NDGA) as compared with celecoxib in puromycin aminonucleoside (PAN) nephrosis rats." | 7.75 | Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat. ( Chung, HC; Kwak, IS; Lee, DW; Lee, MY; Lee, SB; Seong, EY; Sol, MY; Song, SH; Yang, BY, 2009) |
| "The present study aimed to assess the effects of a COX-2 inhibitor, celecoxib, a HMG-CoA reductase inhibitor, atorvastatin, and the association of both on monocrotaline (MC)-induced pulmonary hypertension in rats." | 7.74 | Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. ( Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L, 2008) |
| " Celecoxib (CX) and minocycline hydrochloride (MH) have both been widely used in treating breast cancer; however, their combined effects on the osseous metastasis of breast cancer have not yet been studied." | 7.74 | The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| " Here, we investigate the effects of the selective cyclo-oxygenase-2 inhibitor, celecoxib, in rats subjected to experimental colitis." | 7.71 | Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. ( Caputi, AP; Centorrino, T; Ciccolo, A; Cuzzocrea, S; Dugo, L; Mazzon, E; Sautebin, L; Serraino, I, 2001) |
| "Celecoxib was administered i." | 5.31 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. ( Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001) |
| "We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
| "Chronic inflammation is one of the main symptoms of cancer cachexia, and cyclooxygenase 2 inhibitors, such as celecoxib, may be beneficial in counteracting the major symptoms of this syndrome." | 3.81 | Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor. ( Bi, Y; Han, M; Jiang, M; Xu, X; Zhang, Y, 2015) |
| "Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis." | 3.80 | Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice. ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| " We report in this study that a clinically available COX-2 inhibitor, celecoxib, exacerbates porcine serum (PS)-induced hepatic fibrosis and induces hepatocellular necrosis in an experimental liver fibrosis model." | 3.75 | Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. ( Li, X; Liu, H; Wei, W, 2009) |
| " The present study was designed to investigate the anti-proteinuric effects of nordihydroguaiaretic acid (NDGA) as compared with celecoxib in puromycin aminonucleoside (PAN) nephrosis rats." | 3.75 | Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat. ( Chung, HC; Kwak, IS; Lee, DW; Lee, MY; Lee, SB; Seong, EY; Sol, MY; Song, SH; Yang, BY, 2009) |
| "The present study aimed to assess the effects of a COX-2 inhibitor, celecoxib, a HMG-CoA reductase inhibitor, atorvastatin, and the association of both on monocrotaline (MC)-induced pulmonary hypertension in rats." | 3.74 | Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. ( Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L, 2008) |
| " Celecoxib (CX) and minocycline hydrochloride (MH) have both been widely used in treating breast cancer; however, their combined effects on the osseous metastasis of breast cancer have not yet been studied." | 3.74 | The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| " Here, we investigate the effects of the selective cyclo-oxygenase-2 inhibitor, celecoxib, in rats subjected to experimental colitis." | 3.71 | Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. ( Caputi, AP; Centorrino, T; Ciccolo, A; Cuzzocrea, S; Dugo, L; Mazzon, E; Sautebin, L; Serraino, I, 2001) |
| "This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily." | 2.73 | Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. ( Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C, 2007) |
| "Cancer cachexia is a devastating syndrome of advanced malignancy which negatively impacts on patients' morbidity, mortality and quality of life." | 2.49 | Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. ( Cantwell, MM; Hughes, CM; Murray, LJ; Parsons, C; Reid, J, 2013) |
| " This study aimed to investigate the anti-cancer potential of PPAR-γ agonist Pioglitazone combined with COX-2 inhibitor Celelcoxib in NSCLC." | 1.72 | Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer. ( Kiran, AVVVR; Krishnamurthy, PT; Kumari, GK, 2022) |
| "Celecoxib has also a possible involvement with redox homeostasis, because its administration caused significant changes in the activity of oxidative enzymes, such as catalase and superoxide dismutase." | 1.36 | Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. ( Acco, A; Ávila, TV; Bastos-Pereira, AL; Cadena, SM; Cristina da Silva de Assis, H; Donatti, L; Lugarini, D; Muscará, MN; Oliveira-Christoff, Ad; Pires, Ado R; Teixeira, S, 2010) |
| "Celecoxib-treated rats had statistically significant decreases of cholesterol, total bilirubin, total protein, urea, globulin, blood urea nitrogen, phosphorus, and calcium." | 1.36 | Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats. ( Akay, MT; Kismet, K; Koçkaya, EA; Selmanoğlu, G, 2010) |
| "Body weight was increased significantly and similarly in HFa, HFa-Cel, and HFa-Mes." | 1.35 | COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. ( Chan, PC; Chen, CH; Chiang, CF; Hsieh, PS; Jin, JS; Shih, KC, 2009) |
| "Celecoxib treatment inhibited VEGF mRNA expression without any significant reduction in cyclooxygenase-2 mRNA." | 1.32 | Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. ( Ayalasomayajula, SP; Kompella, UB, 2003) |
| "Treatment with celecoxib was examined and compared to treatment with the general NSAID, ibuprofen, and to a control group receiving only dimethylbenz(a)anthracene." | 1.31 | Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. ( Abou-Issa, H; Alshafie, GA; Harris, RE; Seibert, K, 2000) |
| "Celecoxib was administered i." | 1.31 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. ( Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001) |
| " Experiments were designed to assess the potential chemopreventive properties of highly selective iNOS inhibitors, administered individually and in combination with a selective COX-2 inhibitor, on the development of AOM-induced colonic aberrant crypt foci (ACF)." | 1.31 | Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. ( Connor, JR; Indranie, C; Manning, PT; Rao, CV; Reddy, BS; Simi, B, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 22 (57.89) | 29.6817 |
| 2010's | 14 (36.84) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Kiran, AVVVR | 1 |
| Kumari, GK | 1 |
| Krishnamurthy, PT | 1 |
| Kumar, JSD | 1 |
| Bai, B | 1 |
| Zanderigo, F | 1 |
| DeLorenzo, C | 1 |
| Prabhakaran, J | 1 |
| Parsey, RV | 1 |
| Mann, JJ | 1 |
| Sakurai, T | 1 |
| Fujimori, S | 1 |
| Hayashida, M | 1 |
| Hanada, R | 1 |
| Akiyama, J | 1 |
| Sakamoto, C | 1 |
| Safaeian, L | 1 |
| Hajhashemi, V | 1 |
| Ajoodanian, M | 1 |
| Wong, TY | 1 |
| Li, F | 1 |
| Lin, SM | 1 |
| Chan, FL | 1 |
| Chen, S | 1 |
| Leung, LK | 1 |
| Xu, X | 1 |
| Jiang, M | 1 |
| Zhang, Y | 1 |
| Bi, Y | 1 |
| Han, M | 1 |
| Balansky, R | 1 |
| Ganchev, G | 1 |
| Iltcheva, M | 1 |
| Nikolov, M | 1 |
| La Maestra, S | 1 |
| Micale, RT | 1 |
| D'Agostini, F | 1 |
| Steele, VE | 1 |
| De Flora, S | 1 |
| Liu, Y | 1 |
| Cui, Y | 1 |
| Chen, Y | 1 |
| Gao, X | 1 |
| Su, Y | 1 |
| Cui, L | 1 |
| Lu, CH | 1 |
| Hung, YJ | 1 |
| Hsieh, PS | 2 |
| Pallio, G | 1 |
| Bitto, A | 1 |
| Pizzino, G | 1 |
| Galfo, F | 1 |
| Irrera, N | 1 |
| Minutoli, L | 1 |
| Arcoraci, V | 1 |
| Squadrito, G | 1 |
| Macrì, A | 1 |
| Squadrito, F | 1 |
| Altavilla, D | 1 |
| Egashira, I | 1 |
| Takahashi-Yanaga, F | 1 |
| Nishida, R | 1 |
| Arioka, M | 1 |
| Igawa, K | 1 |
| Tomooka, K | 1 |
| Nakatsu, Y | 1 |
| Tsuzuki, T | 1 |
| Nakabeppu, Y | 1 |
| Kitazono, T | 1 |
| Sasaguri, T | 1 |
| Rakotoniaina, Z | 1 |
| Guerard, P | 1 |
| Lirussi, F | 1 |
| Rochette, L | 1 |
| Dumas, M | 1 |
| Goirand, F | 1 |
| Bardou, M | 1 |
| Niu, G | 1 |
| Liao, Z | 1 |
| Cai, L | 1 |
| Wei, R | 1 |
| Sun, L | 1 |
| Cheruvu, NP | 1 |
| Amrite, AC | 1 |
| Kompella, UB | 2 |
| Liu, H | 1 |
| Wei, W | 1 |
| Li, X | 1 |
| Lee, DW | 1 |
| Kwak, IS | 1 |
| Lee, SB | 1 |
| Song, SH | 1 |
| Seong, EY | 1 |
| Chung, HC | 1 |
| Yang, BY | 1 |
| Lee, MY | 1 |
| Sol, MY | 1 |
| Jin, JS | 1 |
| Chiang, CF | 1 |
| Chan, PC | 1 |
| Chen, CH | 1 |
| Shih, KC | 1 |
| Koul, A | 1 |
| Tanwar, L | 1 |
| Arora, N | 1 |
| Bastos-Pereira, AL | 1 |
| Lugarini, D | 1 |
| Oliveira-Christoff, Ad | 1 |
| Ávila, TV | 1 |
| Teixeira, S | 1 |
| Pires, Ado R | 1 |
| Muscará, MN | 1 |
| Cadena, SM | 1 |
| Donatti, L | 1 |
| Cristina da Silva de Assis, H | 1 |
| Acco, A | 1 |
| Jiao, W | 1 |
| Kiang, JG | 1 |
| Cary, L | 1 |
| Elliott, TB | 1 |
| Pellmar, TC | 1 |
| Ledney, GD | 1 |
| Koçkaya, EA | 1 |
| Selmanoğlu, G | 1 |
| Kismet, K | 1 |
| Akay, MT | 1 |
| Suddek, GM | 1 |
| El-Kenawi, AE | 1 |
| Abdel-Aziz, A | 1 |
| El-Kashef, HA | 1 |
| Reid, J | 1 |
| Hughes, CM | 1 |
| Murray, LJ | 1 |
| Parsons, C | 1 |
| Cantwell, MM | 1 |
| Schwartz, JI | 2 |
| Vandormael, K | 1 |
| Malice, MP | 1 |
| Kalyani, RN | 1 |
| Lasseter, KC | 2 |
| Holmes, GB | 1 |
| Gertz, BJ | 2 |
| Gottesdiener, KM | 2 |
| Laurenzi, M | 1 |
| Redfern, KJ | 1 |
| Brune, K | 1 |
| Swiergiel, AH | 1 |
| Dunn, AJ | 1 |
| Ayalasomayajula, SP | 1 |
| Hausman, N | 1 |
| Beharry, K | 1 |
| Nishihara, K | 1 |
| Akmal, Y | 1 |
| Asrat, T | 1 |
| Chen, X | 1 |
| Wang, S | 1 |
| Wu, N | 1 |
| Sood, S | 1 |
| Wang, P | 1 |
| Jin, Z | 1 |
| Beer, DG | 1 |
| Giordano, TJ | 1 |
| Lin, Y | 1 |
| Shih, WC | 1 |
| Lubet, RA | 2 |
| Yang, CS | 1 |
| Stichtenoth, DO | 1 |
| Marhauer, V | 1 |
| Tsikas, D | 1 |
| Gutzki, FM | 1 |
| Frölich, JC | 1 |
| Nakai, K | 1 |
| Tanaka, S | 1 |
| Sakai, A | 1 |
| Nagashima, M | 1 |
| Tanaka, M | 1 |
| Otomo, H | 1 |
| Nakamura, T | 1 |
| Lai, V | 1 |
| George, J | 1 |
| Richey, L | 1 |
| Kim, HJ | 1 |
| Cannon, T | 1 |
| Shores, C | 1 |
| Couch, M | 1 |
| Thach, C | 1 |
| Miller, J | 1 |
| Hreniuk, D | 1 |
| Hilliard, DA | 1 |
| Snyder, KM | 1 |
| Fischer, SM | 1 |
| Lo, HH | 1 |
| Gordon, GB | 1 |
| Seibert, K | 2 |
| Kelloff, G | 1 |
| Conti, CJ | 1 |
| Harris, RE | 1 |
| Alshafie, GA | 1 |
| Abou-Issa, H | 1 |
| Blumenthal, RD | 1 |
| Waskewich, C | 1 |
| Goldenberg, DM | 1 |
| Lew, W | 1 |
| Flefleh, C | 1 |
| Burton, J | 1 |
| Cuzzocrea, S | 1 |
| Mazzon, E | 1 |
| Serraino, I | 1 |
| Dugo, L | 1 |
| Centorrino, T | 1 |
| Ciccolo, A | 1 |
| Sautebin, L | 1 |
| Caputi, AP | 1 |
| Rao, CV | 1 |
| Indranie, C | 1 |
| Simi, B | 1 |
| Manning, PT | 1 |
| Connor, JR | 1 |
| Reddy, BS | 1 |
| Medhurst, SJ | 1 |
| Walker, K | 1 |
| Bowes, M | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Muller, M | 1 |
| Hattenberger, M | 1 |
| Vaxelaire, J | 1 |
| O'Reilly, T | 1 |
| Wotherspoon, G | 1 |
| Winter, J | 1 |
| Green, J | 1 |
| Urban, L | 1 |
1 review available for celecoxib and Body Weight
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cachexia; Celecoxib; Cyclooxygenase 2 I | 2013 |
5 trials available for celecoxib and Body Weight
| Article | Year |
|---|---|
Repeatability of small bowel transit time in capsule endoscopy in healthy subjects.
Topics: Adult; Aged; Body Weight; Capsule Endoscopy; Celecoxib; Female; Gastrointestinal Transit; Healthy Vo | 2018 |
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Celecoxib; Creatinine; Cyclooxygenase Inhibito | 2002 |
Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Body Weight; Celecoxib; Creatinine; Cross-Over Stu | 2005 |
Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract.
Topics: Body Mass Index; Body Weight; C-Reactive Protein; Cachexia; Celecoxib; Cyclooxygenase Inhibitors; Cy | 2008 |
Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agent | 2007 |
32 other studies available for celecoxib and Body Weight
| Article | Year |
|---|---|
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung | 2022 |
In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [
Topics: Animals; Body Weight; Brain; Carbon Radioisotopes; Celecoxib; Female; Ligands; Magnetic Resonance Im | 2018 |
The effect of celecoxib on blood pressure and plasma oxidant/antioxidant status in co-administration with glucocorticoid in rat.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Captopril; Celecoxib; Dexamethasone; Diastole; G | 2018 |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Topics: Animals; Apoptosis; Aromatase; Aspirin; Body Weight; Breast Neoplasms; Celecoxib; Cell Cycle; Cycloo | 2014 |
Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
Topics: Anemia; Animals; Antibodies, Monoclonal; Body Weight; Cachexia; Celecoxib; Cell Line, Tumor; Cycloox | 2015 |
Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Body Weight; Celecoxib; C | 2015 |
Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats.
Topics: Animals; Antirheumatic Agents; Biomarkers; Body Weight; Bone and Bones; Bone Density; Bone Resorptio | 2015 |
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body | 2016 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin | 2016 |
Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway.
Topics: Animals; beta Catenin; Blood Cell Count; Body Weight; Celecoxib; Cell Line, Tumor; DNA Glycosylases; | 2017 |
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxy | 2008 |
The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice.
Topics: Alkaline Phosphatase; Animals; Apoptosis; Body Weight; Bone Neoplasms; Breast Neoplasms; Celecoxib; | 2008 |
Effect of diabetes on transscleral delivery of celecoxib.
Topics: Animals; Area Under Curve; Blood Glucose; Blood-Retinal Barrier; Body Weight; Capillary Permeability | 2009 |
Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum.
Topics: Animals; Body Weight; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors | 2009 |
Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Celecoxib; Creatinine; Cyclooxygenase | 2009 |
COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Animals; Blood Glucose; Body Weight; Celecoxib; Cell Size; | 2009 |
Celecoxib administration exhibits tissue specific effect on 3H-benzo(a)pyrene-DNA adduct formation in cigarette smoke inhaling mice.
Topics: Administration, Oral; Animals; Benzo(a)pyrene; Body Weight; Celecoxib; Cytochrome P-450 Enzyme Syste | 2009 |
Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Body Weight; Catalase; Celecoxib; Cyclooxygenase 2; C | 2010 |
COX-2 inhibitors are contraindicated for treatment of combined injury.
Topics: Animals; Body Weight; Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Cytokines; Dinoprosto | 2009 |
Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats.
Topics: Administration, Oral; Animals; Body Weight; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Re | 2010 |
Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of Cisplatin-induced nephrotoxicity.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Body Weight; Celecoxib; Ci | 2011 |
Distinct roles for cyclooxygenases 1 and 2 in interleukin-1-induced behavioral changes.
Topics: Animals; Behavior, Animal; Body Weight; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenas | 2002 |
Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.
Topics: Animals; Blood Glucose; Body Weight; Capillary Permeability; Celecoxib; Cornea; Cyclooxygenase 2; Cy | 2003 |
Antenatal administration of celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, appears to improve placental perfusion in the pregnant rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2003 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonat | 2004 |
Cyclooxygenase-2 selective inhibition suppresses restoration of tibial trabecular bone formation in association with restriction of osteoblast maturation in skeletal reloading after hindlimb elevation of mice.
Topics: Animals; Body Weight; Bone Development; Celecoxib; Cyclooxygenase 2 Inhibitors; Hindlimb Suspension; | 2006 |
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Celecoxib; Cell Division; Cyclooxygen | 1999 |
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxy | 2000 |
Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Blottin | 2001 |
Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonates; Body Weight; Celecoxib; Colitis | 2001 |
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Body Weight; Carcinogens; Celecoxib; Colon; Colonic | 2002 |
A rat model of bone cancer pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Body Tempera | 2002 |